^
    7ms
    REVOLUTION: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Parker Institute for Cancer Immunotherapy | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • albumin-bound paclitaxel • hydroxychloroquine • NG-350A
    1year
    Safe and effective delivery of antibody fragments to the solid tumor microenvironment (AACR 2023)
    NG-350A is currently being evaluated in phase I clinical studies in combination with Pembrolizumab or Ipilimumab. Data from these studies with initial vectors encoding combinations of functionally active antibody fragments will be presented. Collectively, these clinical and preclinical datasets demonstrate the broad utility of the T-SIGn platform for expressing rationally-designed combinations of antibodies and other natural and synthetic agents within tumors and thus enabling the development of new and potent immunotherapies for patients with solid epithelial cancers.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL17A (Interleukin 17A)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • NG-350A